Literature DB >> 20576283

Micro-RNA-181a regulates osteopontin-dependent metastatic function in hepatocellular cancer cell lines.

Syamal D Bhattacharya1, Juline Garrison, Hongtao Guo, Zhiyong Mi, Jovan Markovic, Victoria M Kim, Paul C Kuo.   

Abstract

BACKGROUND: Osteopontin (OPN) is a variably expressed, secreted glycophosphoprotein that mediates the growth and metastases of hepatocellular cancer (HCC). MicroRNAs (miRNAs) may be responsible for variant OPN expression, interrupting translation by binding OPN messenger RNA (mRNA) in 3'-untranslated regions (UTRs).
METHODS: A microarray analysis identified miRNAs of interest. Plasmid constructs using a luciferase reporter with variable OPN 3'UTR mutations were transfected into 2 HCC cell lines to determine miRNA regulation of OPN expression. Western blot analyses confirmed variable OPN expression in both cell lines. Invasion, adhesion, and migration evaluated metastatic behavior in Hep G2 and Hep 3B with modified miRNA and OPN expression.
RESULTS: Hep 3B produces 36 x miRNA 181a compared with Hep G2. Luciferase activity after transfection with miRNA 181a precursor was decreased in both cell lines (P < .01); luciferase activity increased with miRNA 181a inhibitor transfection in both cell lines (P < .01). Hep 3B transfected with mutated OPN 3'UTR increased luciferase activity 108% (P < .01). Hep G2 transfected with miRNA precursor decreased OPN expression 5 x (P < .01) in Western blot analyses. Hep 3B transfection with miRNA precursor increased OPN expression 3 x (P < .01) in Western blot analyses. In vitro metastatic correlates increased in Hep 3B lines after transfection with siOPN and/or miRNA 181a inhibitor (P < .01).
CONCLUSION: MiRNA 181a decreases OPN expression in HCC cell lines. This previously undescribed mechanism may confer metastatic characteristics to HCC. Copyright 2010 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20576283      PMCID: PMC2905491          DOI: 10.1016/j.surg.2010.05.007

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  12 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Overexpression of osteopontin in hepatocellular carcinoma.

Authors:  Masahiro Gotoh; Michiie Sakamoto; Kengo Kanetaka; Makoto Chuuma; Setsuo Hirohashi
Journal:  Pathol Int       Date:  2002-01       Impact factor: 2.534

Review 3.  The role of osteopontin in tumorigenesis and metastasis.

Authors:  A J Oates; R Barraclough; P S Rudland
Journal:  Invasion Metastasis       Date:  1997

4.  Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells.

Authors:  J Dai; L Peng; K Fan; H Wang; R Wei; G Ji; J Cai; B Lu; B Li; D Zhang; Y Kang; M Tan; W Qian; Y Guo
Journal:  Oncogene       Date:  2009-07-13       Impact factor: 9.867

5.  Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma.

Authors:  Hung-Wei Pan; Yueh-Hsing Ou; Shian-Yang Peng; Shu-Hsian Liu; Po-Lin Lai; Po-Hwaung Lee; Jin-Chuan Sheu; Chi-Ling Chen; Hey-Chi Hsu
Journal:  Cancer       Date:  2003-07-01       Impact factor: 6.860

6.  MicroRNA expression in cytogenetically normal acute myeloid leukemia.

Authors:  Guido Marcucci; Michael D Radmacher; Kati Maharry; Krzysztof Mrózek; Amy S Ruppert; Peter Paschka; Tamara Vukosavljevic; Susan P Whitman; Claudia D Baldus; Christian Langer; Chang-Gong Liu; Andrew J Carroll; Bayard L Powell; Ramiro Garzon; Carlo M Croce; Jonathan E Kolitz; Michael A Caligiuri; Richard A Larson; Clara D Bloomfield
Journal:  N Engl J Med       Date:  2008-05-01       Impact factor: 91.245

7.  RNA stability regulates differential expression of the metastasis protein, osteopontin, in hepatocellular cancer.

Authors:  Sirisha Emani; Jinping Zhang; Lucie Guo; Hongtao Guo; Paul C Kuo
Journal:  Surgery       Date:  2008-04-18       Impact factor: 3.982

8.  hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells.

Authors:  Lei Shi; Zihao Cheng; Junxia Zhang; Rui Li; Peng Zhao; Zhen Fu; Yongping You
Journal:  Brain Res       Date:  2008-07-30       Impact factor: 3.252

Review 9.  Osteopontin: regulation in tumor metastasis.

Authors:  Philip Y Wai; Paul C Kuo
Journal:  Cancer Metastasis Rev       Date:  2008-03       Impact factor: 9.264

10.  Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis.

Authors:  Douglas R Hurst; Mick D Edmonds; Gary K Scott; Christopher C Benz; Kedar S Vaidya; Danny R Welch
Journal:  Cancer Res       Date:  2009-02-03       Impact factor: 12.701

View more
  21 in total

Review 1.  Role of osteopontin in the pathophysiology of cancer.

Authors:  Lalita A Shevde; Rajeev S Samant
Journal:  Matrix Biol       Date:  2014-03-19       Impact factor: 11.583

2.  Green tea component epigallocatechin-3-gallate decreases expression of osteopontin via a decrease in mRNA half-life in cell lines of metastatic hepatocellular carcinoma.

Authors:  Matthew A C Zapf; Anai N Kothari; Cynthia E Weber; Matthew L Arffa; Phillip Y Wai; Joseph Driver; Gopal N Gupta; Paul C Kuo; Zhiyong Mi
Journal:  Surgery       Date:  2015-07-17       Impact factor: 3.982

Review 3.  MicroRNAs dysregulation in hepatocellular carcinoma: Insights in genomic medicine.

Authors:  Iván Lyra-González; Laura E Flores-Fong; Ignacio González-García; David Medina-Preciado; Juan Armendáriz-Borunda
Journal:  World J Hepatol       Date:  2015-06-18

Review 4.  Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers.

Authors:  Dong-Xing Cao; Zhi-Jie Li; Xiao-Ou Jiang; Yick Liang Lum; Ester Khin; Nikki P Lee; Guo-Hao Wu; John M Luk
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742

5.  Genetic association of osteopontin (OPN) and its receptor CD44 genes with susceptibility to Chinese gastric cancer patients.

Authors:  Yue Qiu; Yuan Hu; Zuo-Yang Zhang; Lei Ye; Fei-Hong Xu; Marion E Schneider; Xue-Ling Ma; Yi-Xin Du; Xian-Bo Zuo; Fu-Sheng Zhou; Gang Chen; Xu-Shi Xie; Yan Zhang; Hong-Zhen Xia; Ji-Feng Wu; Wei-Dong Du
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-10       Impact factor: 4.553

6.  miR181a protects against angiotensin II-induced osteopontin expression in vascular smooth muscle cells.

Authors:  Ebony Washington Remus; Alicia N Lyle; Daiana Weiss; Natalia Landàzuri; Martina Weber; Charles Searles; W Robert Taylor
Journal:  Atherosclerosis       Date:  2013-02-05       Impact factor: 5.162

7.  MicroRNA-181a functions as an oncomir in gastric cancer by targeting the tumour suppressor gene ATM.

Authors:  Xiangyang Zhang; Yuqiang Nie; Xiaorong Li; Guifu Wu; Qun Huang; Jie Cao; Yanlei Du; Junda Li; Ruoyu Deng; Dongshen Huang; Baozhi Chen; Shang Li; Baojun Wei
Journal:  Pathol Oncol Res       Date:  2014-02-16       Impact factor: 3.201

8.  Gene regulation is governed by a core network in hepatocellular carcinoma.

Authors:  Zuguang Gu; Chenyu Zhang; Jin Wang
Journal:  BMC Syst Biol       Date:  2012-05-01

9.  Cholinesterase-Targeting microRNAs Identified in silico Affect Specific Biological Processes.

Authors:  Geula Hanin; Hermona Soreq
Journal:  Front Mol Neurosci       Date:  2011-10-05       Impact factor: 5.639

10.  Genome-wide analysis of miRNA signature differentially expressed in doxorubicin-resistant and parental human hepatocellular carcinoma cell lines.

Authors:  Jufeng Zhang; Ying Wang; Pingping Zhen; Xia Luo; Chao Zhang; Lin Zhou; Yanxin Lu; Yang Yang; Wei Zhang; Jun Wan
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.